Previous studies have shown that the CD8:Treg ratio is an important indicator of therapeutic benefit in melanomas, where potent synergistic effects of combination therapy using BRAFi and PD1 blockade cause increased CD8+:Treg ratio and enhanced cytokine production, compared with BRAFi alone in both mice and humans [30]. The gene discussed is CD8A; the disease is melanoma.